Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Article

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.

Related Videos
Juanita Mora, MD
Importance of maternal influenza vaccination recommendations
Samantha Olson, MPH
Related Content
FDA approves tovorafenib for most common form of childhood brain tumor | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024
Article

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

April 23rd 2024
Article

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

FDA accepts BLA for meningococcal ABCWY vaccine, target action date set | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA accepts BLA for meningococcal ABCWY vaccine, target action date set

April 16th 2024
Article

The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.

RSV monoclonal antibody nirsevimab to be 5% more expensive | Image Credit: © Peter Hansen - © Peter Hansen - stock.adobe.com.

RSV monoclonal antibody nirsevimab to be 5% more expensive

April 15th 2024
Article

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.

© 2024 MJH Life Sciences

All rights reserved.